Evidence map›Paper›PMID 36547158›Full record

ArticleCurrent oncology (Toronto, Ont.)2022

A Phase I Study of the Non-Receptor Kinase Inhibitor Bosutinib in Combination with Pemetrexed in Patients with Selected Metastatic Solid Tumors.

Nagla Abdel Karim, Asad Ullah, Hongkun Wang, Mahran Shoukier, Steven Pulliam, Ahmed Khaled, Nikhil Patel, John C Morris

Open access · goldAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Tyrosine phosphoproteome profiling identifies cell-intrinsic signals limiting the efficacy of tyrosine kinase inhibitor therapies.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 2 countries.

Nagla Abdel KarimDepartment of Medicine, Inova Schar Cancer Institute, University of Virginia, Fairfax, VA 22031, USA.
Asad UllahDepartment of Pathology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID 0000-0002-9435-9625
Hongkun WangDepartment of Statistics, Georgetown University, Washington, DC 20057, USA.
Mahran ShoukierDepartment of Hematology-Oncology, Georgia Cancer Center, Augusta, GA 30906, USA.
Steven PulliamDepartment of Surgery, The University of Tennessee at Chattanooga, Chattanooga, TN 37403, USA.
Ahmed KhaledDepartment of Medicine, Hematology-Oncology, University of Cincinnati, Cincinnati, OH 45219, USA.
Nikhil PatelDepartment of Pathology, Augusta University Medical Center, Augusta, GA 30906, USA.ORCID 0000-0001-9335-0082
John C MorrisDepartment of Medicine, Hematology-Oncology, University of Cincinnati, Cincinnati, OH 45219, USA.
University of Cincinnati · USAugusta University Health · USGeorgetown University · USNational Cancer Center of Georgia · GEUniversity of Tennessee at Chattanooga · USVanderbilt University Medical Center · USVirginia Cancer Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Src is overexpressed in various cancers, including 27% of non-small cell lung cancer NSCLC, and is correlated with poor clinical outcomes. We hypothesize that Src kinase inhibitors, including Bosutinib, may exhibit clinical synergy in combination with the antifolate drug pemetrexed. In this Phase I, dose-escalation, safety, and maximum tolerated dose (MTD)-determining study, 14 patients with advanced metastatic solid tumors that had progressed on "standard of care" chemotherapy were enrolled in a 3 + 3 dose escalation study. Oral Bosutinib was administered once daily beginning on day 1, where the first cohort started at an oral dose of 200 mg daily with pemetrexed 500 mg/m

Indexed as

AdenocarcinomaAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCarcinoma, Transitional CellLung NeoplasmsUrinary Bladder NeoplasmsAniline CompoundsDisease ProgressionHumansNitrilesPemetrexedProtein Kinase InhibitorsQuinolinesAniline CompoundsAntineoplastic AgentsbosutinibNitrilesPemetrexedProtein Kinase InhibitorsQuinolinesadenocarcinomaBosutinibchemotherapychronic myelocytic leukemia

Identifiers

PMID36547158
PMCPMC9776616
OpenAlexW4311625660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.